Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Shadman on Zanubrutinib in Acalabrutinib-Intolerant Patients With B-cell Malignancies

December 11th 2022

Mazyar Shadman, MD, MPH, discusses the examination of zanubrutinib in patients with B-cell malignancies who were intolerant to acalabrutinib.

Pirtobrutinib Shows High Response Rates in Heavily Pretreated Waldenström Macroglobulinemia

December 11th 2022

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.

REGAL Trial Receives Green Light to Continue Testing Galinpepimut-S in AML

December 9th 2022

The phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia will continue as planned without modifications following a recommendation from the Independent Data Monitoring Committee.

Development of Zandelisib for B-cell Malignancies Discontinued Outside of Japan

December 6th 2022

The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.

FDA Grants Breakthrough Therapy Designation to Revumenib in Relapsed/Refractory KMT2A-rearranged Acute Leukemia

December 6th 2022

The FDA has granted a breakthrough therapy designation to revumenib for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Unmet Needs and Future Directions in Care for Relapsed/Refractory FL

December 6th 2022

Closing out her discussion on novel therapy for relapsed/refractory follicular lymphoma, Lori Leslie, MD, highlights unmet needs and considers future evolutions in the treatment paradigm.

Practical Selection of Novel Therapy for Relapsed/Refractory Follicular Lymphoma

December 6th 2022

Insight to the factors that help select optimal third-line treatment for patients with follicular lymphoma in the context of available novel therapies.

Leading by Example

December 3rd 2022

A girl who grew up in a small South Dakota town, Julie M. Vose, MD, MBA, grew into a dynamo who revolutionized lymphoma treatment and led the most prominent oncology organization in the world.

PI3K Inhibitors Face Challenges in Hematologic Malignancies

December 2nd 2022

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

FDA Approves Olutasidenib for IDH1-Mutated Relapsed/Refractory AML

December 1st 2022

The FDA has approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation as detected by an FDA-approved test.

FDA Accepts BLA of Denileukin Diftitox Reformulation for Persistent or Recurrent Cutaneous T-cell Lymphoma

December 1st 2022

The FDA has accepted a biologics license application seeking the approval of a reformulation of denileukin diftitox for use as a potential therapeutic option in patients with persistent or recurrent cutaneous T-cell lymphoma.

Novel Third-Line Therapies for Relapsed/Refractory Follicular Lymphoma

November 30th 2022

A comprehensive overview of the third-line treatment armamentarium for patients with relapsed/refractory follicular lymphoma.

Relapsed/Refractory Follicular Lymphoma: Sequencing Through Multiple Lines of Therapy

November 30th 2022

Key opinion leader Lori Leslie, MD, sheds light on the optimal sequencing of therapy throughout multiple lines of follicular lymphoma.

Dr. Brody on Updated Data From the ECHELON-1 Trial in Hodgkin Lymphoma

November 29th 2022

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

FDA Grants RMAT, Fast Track Designations to CB-010 in Relapsed/Refractory Non-Hodgkin Lymphoma

November 29th 2022

The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

FDA Extends PDUFA Date for BLA of Omidubicel in Blood Cancers Requiring Transplant

November 23rd 2022

The FDA has extended the Prescription Drug User Fee Act goal date to May 1, 2023, for the biologics license application seeking the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.

Assessing Response to Therapy and High-Risk Disease in Follicular Lymphoma

November 23rd 2022

An expert’s perspective on assessing response to therapy in follicular lymphoma and the parameters used to identify high-risk disease.

Overview on Follicular Lymphoma and A Patient Case of Relapsed/Refractory Disease

November 23rd 2022

Expert hematologist-oncologist Lori Leslie, MD, provides insight to the incidence and prognosis of follicular lymphoma, highlighting a patient case of refractory disease.

Zandelisib Elicits High Response Rates in Indolent Non-Hodgkin Lymphoma

November 21st 2022

The oral PI3Kδ inhibitor zandelisib produced an overall response rate in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström macroglobulinemia.

FDA Approves Additional Dosing Schedule for Rylaze in ALL and LBL

November 18th 2022

The FDA has approved a supplemental biologics license application to add a Monday/Wednesday/Friday intramuscular dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze).